IRIS Accounts Production v24.2.0.383 10155257 Board of Directors 1.1.23 31.12.23 31.12.23 11/9/2024 0 0 false true false false true false Auditors Opinion Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh101552572022-12-31101552572023-12-31101552572023-01-012023-12-31101552572021-12-31101552572022-01-012022-12-31101552572022-12-3110155257ns15:EnglandWales2023-01-012023-12-3110155257ns14:PoundSterling2023-01-012023-12-3110155257ns10:Director12023-01-012023-12-3110155257ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3110155257ns10:SmallEntities2023-01-012023-12-3110155257ns10:Audited2023-01-012023-12-3110155257ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3110155257ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3110155257ns10:FullAccounts2023-01-012023-12-3110155257ns10:OrdinaryShareClass12023-01-012023-12-3110155257ns10:Director32023-01-012023-12-3110155257ns10:RegisteredOffice2023-01-012023-12-3110155257ns5:CurrentFinancialInstruments2023-12-3110155257ns5:CurrentFinancialInstruments2022-12-3110155257ns5:ShareCapital2023-12-3110155257ns5:ShareCapital2022-12-3110155257ns5:CapitalRedemptionReserve2023-12-3110155257ns5:CapitalRedemptionReserve2022-12-3110155257ns5:RetainedEarningsAccumulatedLosses2023-12-3110155257ns5:RetainedEarningsAccumulatedLosses2022-12-3110155257ns5:CostValuation2022-12-3110155257ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3110155257ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-3110155257ns10:OrdinaryShareClass12023-12-3110155257ns5:RetainedEarningsAccumulatedLosses2022-12-3110155257ns5:CapitalRedemptionReserve2022-12-3110155257ns5:RetainedEarningsAccumulatedLosses2023-01-012023-12-31
REGISTERED NUMBER: 10155257 (England and Wales)















GTA Laboratories Limited

Financial Statements

for the Year Ended 31 December 2023






GTA Laboratories Limited (Registered number: 10155257)






Contents of the Financial Statements
for the year ended 31 December 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


GTA Laboratories Limited

Company Information
for the year ended 31 December 2023







DIRECTORS: A Kershaw
TR Phillips





REGISTERED OFFICE: 14-15 Whitehouse Industrial Estate
Runcorn
United Kingdom
Cheshire
WA7 3DL





REGISTERED NUMBER: 10155257 (England and Wales)





AUDITORS: McMillan & Co LLP
Chartered Accountants and
Statutory Auditor
28 Eaton Avenue
Matrix Office Park
Buckshaw Village
Chorley
Lancashire
PR7 7NA

GTA Laboratories Limited (Registered number: 10155257)

Balance Sheet
31 December 2023

2023 2022
Notes £ £ £ £
FIXED ASSETS
Investments 5 1,346,700 1,346,700

CURRENT ASSETS
Debtors 6 8,504 16,006
Cash at bank 161 254,841
8,665 270,847
CREDITORS
Amounts falling due within one year 7 99,630 37,802
NET CURRENT (LIABILITIES)/ASSETS (90,965 ) 233,045
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,255,735

1,579,745

CAPITAL AND RESERVES
Called up share capital 8 4 6
Capital redemption reserve 9 2 -
Retained earnings 9 1,255,729 1,579,739
SHAREHOLDERS' FUNDS 1,255,735 1,579,745

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 11 September 2024 and were signed on its behalf by:





A Kershaw - Director


GTA Laboratories Limited (Registered number: 10155257)

Notes to the Financial Statements
for the year ended 31 December 2023

1. STATUTORY INFORMATION

GTA Laboratories Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


Monetary amounts in these financial statements have been rounded to the nearest £1.

2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements have been prepared under the historical cost convention.

The company has net current liabilities of £90,965 (2022: £233,045 net current assets), following the purchase of own shares in the year. The subsidiaries are profitable and will repatriate funds as required for the company to meet its liabilities. The financial statements have therefore been prepared on a going concern basis.

Preparation of consolidated financial statements
The financial statements contain information about GTA Laboratories Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Investments in subsidiaries
Fixed asset investments are stated at cost less provision for diminution in value.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

GTA Laboratories Limited (Registered number: 10155257)

Notes to the Financial Statements - continued
for the year ended 31 December 2023

3. ACCOUNTING POLICIES - continued

Financial instruments
Financial instruments are classified and accounted for according to the substance of the contractual arrangement as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

4. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2022 - NIL).

5. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£
COST
At 1 January 2023
and 31 December 2023 1,346,700
NET BOOK VALUE
At 31 December 2023 1,346,700
At 31 December 2022 1,346,700

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£ £
Amounts owed by group undertakings 8,500 16,000
Called up share capital not paid 4 6
8,504 16,006

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£ £
Other loans 46,950 -
Amounts owed to group undertakings 18,995 -
Other creditors 8,649 -
Directors' current accounts 18,810 27,800
Accruals and deferred income 6,226 10,002
99,630 37,802

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2023 2022
value: £ £
4 Ordinary £1 4 6

On the 30th June 2023, 2 ordinary shares of £1 each were bought back by the company and immediately cancelled for a consideration of £423,738.

GTA Laboratories Limited (Registered number: 10155257)

Notes to the Financial Statements - continued
for the year ended 31 December 2023

9. RESERVES
Capital
Retained redemption
earnings reserve Totals
£ £ £

At 1 January 2023 1,579,739 - 1,579,739
Profit for the year 290,423 290,423
Dividends (190,695 ) (190,695 )
Purchase of own shares (423,738 ) 2 (423,736 )
At 31 December 2023 1,255,729 2 1,255,731

10. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Neil McMillan FCA (Senior Statutory Auditor)
for and on behalf of McMillan & Co LLP

11. RELATED PARTY DISCLOSURES

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

At the year end the company owed the directors £18,810 (2022: £27,800), interest has been charged at a commercial rate of interest totalling £1,881 in the year (2022: £2,224).

12. ULTIMATE CONTROLLING PARTY

In the opinion of the directors the company is controlled by the directors who owned the entire share capital of the company throughout the period.